Mergers & Acquisitions ·
ASP Isotopes Inc. issued a shareholder letter on August 4, 2026, outlining operational updates and strategic…
ASPIASP Isotopes Inc.
ASP Isotopes Inc. issued a shareholder letter on August 4, 2026, outlining operational updates and strategic developments across its business units ahead of Q2 2026 financial results. The company reported that PET Labs achieved over 50% organic revenue growth in H1 2026, with FY 2026 revenues forecast at approximately $14 million. Renergen expects to commence helium production before September 30, 2026, targeting annualized revenues of $27 million post-Phase 1 completion. Additionally, ASP Isotopes announced a planned reverse merger between its subsidiary Noble Africa LLC and ENDRA Life Sciences Inc., through which ASPI will initially own approximately 89% of the combined Nasdaq-listed entity following a $50 million private placement. The company also confirmed it is in final stages for commercial shipments of Silicon-28 and Ytterbium-176 isotopes during H2 2026. ASP Isotopes Inc. operates as an advanced materials company focused on developing technologies for the production of critical isotopes used in nuclear medicine, semiconductors, and energy.